Formulation And In-Vitro Evaluation of Mouth Dissolving Tablet of Salbutamol Sulphate

Salbutamol sulphate, a short-acting β₂-adrenergic receptor agonist, is widely prescribed for the management of asthma and chronic obstructive pulmonary disease (COPD). Its higher selectivity for β₂-receptors over β₁-receptors ensures targeted pulmonary activity with reduced cardiac side effects. In the present study, mouth dissolving tablets (MDTs) of salbutamol sulphate were developed using the direct compression method with different concentrations of super disintegrants, including croscarmellose sodium, sodium starch glycolate, and crospovidone. The prepared formulations were assessed for pre- and post-compression characteristics such as hardness, friability, weight variation, drug content uniformity, disintegration time, water absorption ratio, wetting time, and in vitro dissolution. All formulations exhibited acceptable weight variation (within ±7.5%), hardness between 3.4–4.0 kg/cm², and friability values below 1%. Disintegration times were found to be less than one minute, while drug content ranged from 98.5% to 101%. Wetting time was recorded at around 8 seconds, with a water absorption ratio of 89.84%. Among all formulations, DC6 containing 7.5% crospovidone demonstrated the most promising results, with a rapid disintegration time of 27 seconds and an in vitro drug release of 98.45% within 18 minutes. These findings confirm that crospovidone is highly effective in producing fast-dissolving salbutamol tablets suitable for rapid onset of action in respiratory conditions.